Bleeding Disorders

More on Altuviiio Assays

Here’s a post from Sacha N. Uljon MD PhD, Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH), Boston, US, describing their experience with Altuviiio measurement using a one-stage clot-based assay and a chromogenic substrate assay. Dr. Uljon references our 3-14-24 discussion “How to Measure Plasma Efanesoctocog Alfa (Altuviiio)” and writes: Hello everyone. I’m […]

Bleeding Disorders

November 2024 QQ: Cryoprecipitate

Our November 2024 Quick Question, which attracted 28 responses, asked, “Who invented cryoprecipitate?” Dr. E. J. Kohn: 1 (4%) Dr. Judith Pool: 19 (68%) Dr. Armand Quick: 3 (11%) Dr. Rudolph Virchow: 4 (13%) Dr. Kenneth Brinhous: 1 (4%) Comments: Cryoprecipitate (Cryo) was developed and produced by Judith Pool, PhD, 1919–1975, from Stanford University in […]

Quick Question Archive

Clot Club: Hemophilia Therapy

on 11/13/2024, Fritsma Factor colleague Dave McGlasson, Clot Club contributor, posted Extended Half-life (EHL) Testing for Factor VIII (FVIII) and Factor IX (FIX) Therapies. His entry provides comprehensive laboratory assay information for managing all current factor concentrates and bypassing therapies.

Bleeding Disorders

Low VWF Classification Dropped by the ISTH

The September 2024 edition of the Journal of Thrombosis and Haemostasis contains a helpful editorial describing the most recently developed classification of von Willebrand disease that drops the classification “Low von Willebrand Factor” that we’ve used to describe people whose VWF level is between 30–50 VWF Units/dL. Click here for the article: Low VWF Enigma […]

Bleeding Disorders

October 2024 QQ Summary: When Do You Order a Bethesda Titer?

This is a follow-up to our 9-30-24 post introducing our October Quick Question, “At what FVIII activity level do you order a Bethesda inhibitor assay (Nijmegen-Bethesda Assay, NBA)?” It occurred to me (Geo) that the demand for NBAs may have diminished with the 2017 release of HemLibra® (emicizumab), the FVIII bypassing therapy, to be followed […]

Bleeding Disorders

Northeast Lab Conference: “Have We Cured Hemophilia?” Handout

George presents “Have We Cured Hemophilia” at the Northeast Laboratory Conference on Wednesday, October 16, 10–11:30. Click here for your 6-slide-per-page full-color handout.

Bleeding Disorders

More on Nijmegen-Bethesda Test Volumes

From Ali Sadeghi-Khomami PhD, Precision BioLogic scientist. Access to national and global testing databases is needed to answer the NBA test order volumes question. I am unsure if such a database exists, but relevant data could also be retrieved from insurance companies to estimate the annual rate of NBA inhibitor assays. Yearly marketing report documents […]

Bleeding Disorders

Nijmegen-Bethesda Test Volumes

This is a follow-up to our 9-30-24 post introducing our October Quick Question, “At what FVIII activity level do you order a Nijmegen-Bethesda inhibitor assay (NBA)?” It occurred to me (Geo) that the demand for NBAs may have diminished with the advent of the FVIII bypassing therapies, HemLibra® (emicizumab), soon to be followed by MIM8 […]

Bleeding Disorders

October 2024 Quick Question: Inhibitors

A 9/5/24 question from Chad Siniard, MD, director of the University of Alabama at Birmingham Hospital coagulation service, generated a discussion on the FVIII level that a facility chooses to generate an order for a Nijmegen-Bethesda FVIII inhibitor assay. Our October 2024 Quick Question (on the right) is a poll that asks, “At what FVIII […]

Bleeding Disorders

September 2024 Quick Question Response

Our September 2024 Quick Question drew 59 responses and asked: “At what FVIII activity level should the PTT become prolonged?” Our answers were: 60 U/dL: 6 (10%) 40 U/dL: 37 (63%) 10 U/dL: 12 (20%) 1 U/dL: 4 (7%) Most of us chose the correct answer. The PTT “partial thromboplastin” manufacturers develop their reagent to […]

Bleeding Disorders

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George holds faculty appointments with Rutgers University and Michigan State University, and is a member of the International Society on Thrombosis and Hemostasis, American Association of Clinical Chemists, and American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question